# The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD

> **NCT02473783** · PHASE2 · COMPLETED · sponsor: **Tri-Service General Hospital** · enrollment: 37 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Sertraline HCl
- **OTHER:** I-123-ADAM SPECT

## Key facts

- **NCT ID:** NCT02473783
- **Lead sponsor:** Tri-Service General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02473783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02473783, "The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT02473783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*